The introduction and subsequent iterations of drug-eluting stent technologies have
substantially improved the efficacy and safety of percutaneous coronary interventions …

Despite on-going evolution and iteration of drug-eluting stent (DES) technology, the
prevalence of in-stent restenosis (ISR) remains relatively unchanged, encompassing≈ 10 …

Aim The guideline for coronary artery revascularization replaces the 2011 coronary artery
bypass graft surgery and the 2011 and 2015 percutaneous coronary intervention guidelines …

The lumen diameter reduction after percutaneous coronary intervention (PCI) is well known
as “restenosis”. This phenomenon is due to vessel remodeling/recoil in case of no-stent …

Interventions. Copies: This document is available on the World Wide Web sites of the
American College of Cardiology (www. cardiosource. org), the American Heart Association …

Management of patients with in-stent restenosis (ISR) remains an important clinical problem.
Although drug-eluting stents (DES) have drastically reduced the incidence of ISR, treatment …

The introduction of the drug-eluting stent (DES) proved to be an important step forward in
reducing rates of restenosis and target lesion revascularization after percutaneous coronary …

Restenosis, defined as the re-narrowing of an arterial lumen after revascularization,
represents an increasingly important issue in clinical practice. Indeed, as the number of stent …

Background Despite the use of modern drug-eluting stents (DES), in-stent restenosis (ISR)
may still occur in as many as 2–10% of percutaneous coronary interventions (PCI) in certain …

Background Preliminary reports of studies involving simple coronary lesions indicate that a
sirolimus-eluting stent significantly reduces the risk of restenosis after percutaneous …